• Explore /
  • Poster
  • / Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.

Abstract Poster

Authors

Eric Van Cutsem

Eric Van Cutsem

University Hospitals Gasthuisberg/Leuven, Leuven, Belgium

Eric Van Cutsem , Manuel Hidalgo , Igor Bazin , Jean-Luc Canon , Elena Poddubskaya , Nebojsa Manojlovic , Michele Milella , Dejan Radenkovic , Chris Verslype , Wei Guo , Lars Damstrup , Pascal Hammel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01016483

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 344)

DOI

10.1200/jco.2015.33.3_suppl.344

Abstract #

344

Poster Bd #

C13

Abstract Disclosures

Similar Posters

First Author: Jean-Luc Van Laethem

First Author: Shintaro Nakano

First Author: Hanno Riess

First Author: Jean-Luc Van Laethem